MIDOL LIQUID GELS Drug Patent Profile

When do Midol Liquid Gels patents expire, and what generic alternatives are available?

Midol Liquid Gels is a drug marketed by Bionpharma and is included in one NDA.

The generic ingredient in MIDOL LIQUID GELS is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-six suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Midol Liquid Gels

A generic version of MIDOL LIQUID GELS was approved as ibuprofen by STRIDES PHARMA INTL on September 24^th, 1986.

Summary for MIDOL LIQUID GELS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	202
Clinical Trials:	1,682
DailyMed Link:	MIDOL LIQUID GELS at DailyMed

Recent Clinical Trials for MIDOL LIQUID GELS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gary Van Guilder	EARLY_PHASE1
Rutgers, The State University of New Jersey	PHASE1
Sakarya University	NA

See all MIDOL LIQUID GELS clinical trials

US Patents and Regulatory Information for MIDOL LIQUID GELS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bionpharma	MIDOL LIQUID GELS	ibuprofen	CAPSULE;ORAL	021472-001	Oct 18, 2002		OTC	Yes	Yes

Expired US Patents for MIDOL LIQUID GELS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bionpharma	MIDOL LIQUID GELS	ibuprofen	CAPSULE;ORAL	021472-001	Oct 18, 2002	6,251,426

EU/EMA Drug Approvals for MIDOL LIQUID GELS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Recordati Rare Diseases	Pedea	ibuprofen	EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.	Authorised	no	no	no	2004-07-28

International Patents for MIDOL LIQUID GELS

See the table below for patents covering MIDOL LIQUID GELS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003508434
Canada	2382292	GELS MOUS CONTENANT DE L'IBUPROFENE (IBUPROFEN-CONTAINING SOFTGELS)
World Intellectual Property Organization (WIPO)	0115688
Austria	357229

Supplementary Protection Certificates for MIDOL LIQUID GELS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1781277	PA2024501	Lithuania		PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726

Market Dynamics and Financial Trajectory for MIDOL LIQUID GELS

Last updated: August 3, 2025

Introduction

MIDOL LIQUID GELS are a prominent over-the-counter (OTC) analgesic product specializing in menstrual pain relief. As a flagship product within the menstrual health segment, MIDOL’s liquid gels combine rapid absorption with targeted pain management, catering to a significant consumer base globally. This analysis delves into the market dynamics influencing MIDOL LIQUID GELS and projects its financial trajectory, factoring in key industry trends, competitive landscape, regulatory environment, and evolving consumer preferences.

Market Landscape and Growth Drivers

The global menstrual health market is experiencing consistent expansion, driven by increasing awareness, shifting cultural attitudes toward women’s health, and rising disposable incomes. According to Grand View Research, the global feminine hygiene market is projected to reach USD 44.4 billion by 2028, growing at a CAGR of over 7% (2021-2028) [1]. MIDOL LIQUID GELS occupy a significant portion of the OTC analgesic segment, which itself is expected to grow due to consumers favoring quick-acting relief products.

Key growth drivers for MIDOL LIQUID GELS include:

• Consumer Demand for Fast Relief: Liquid gels' formulation enables rapid absorption into the bloodstream, making them a preferred choice among consumers seeking immediate alleviation of menstrual discomfort.
• Increased Awareness & Education: Campaigns around menstrual health are destigmatizing discussions, leading to higher product utilization.
• Product Innovation: Introduction of formulations targeting specific symptoms (e.g., bloating, fatigue) alongside pain relief enhances midol’s market appeal.
• Expanding Distribution Channels: Growth in online pharmacies and retail chains increases accessibility.

Competitive Landscape

The OTC analgesic and menstrual product market is highly competitive, featuring key players like Johnson & Johnson (Band-Aid, Tylenol), Pfizer (Advil), and Bayer (Advil, Aleve). MIDOL’s distinctive positioning focuses on menstrual-specific relief, creating niche differentiation.

Competitors also develop similar fast-acting formulations, intensifying market rivalry. Consumer preferences are shifting toward multi-symptom relief products and natural/organic alternatives, posing potential challenges and opportunities for MIDOL.

Regulatory Environment Impact

Regulatory oversight significantly impacts product formulation, marketing, and sales. In the US, the Food and Drug Administration (FDA) regulates OTC analgesics, necessitating compliance with labeling, safety standards, and marketing restrictions. Compliance costs and regulatory changes influence financial planning and product development cycles.

Consumer Trends and Behavioral Shifts

Modern consumers are increasingly health-conscious, inclined toward natural remedies, and demand transparency. These trends influence MIDOL’s product innovation strategies, including potential diversification into organic ingredients or natural anti-inflammatories.

Moreover, rising digital engagement allows targeted marketing, customer feedback integration, and data-driven product customization, which can translate into increased sales.

Financial Trajectory Analysis

Revenue Growth Outlook

Based on historical data and market projections, MIDOL LIQUID GELS are expected to see a compound annual growth rate (CAGR) of approximately 6-8% over the next five years. The growth is driven by:

• Rising demand for menstrual pain relief products.
• Expansion into emerging markets with growing healthcare infrastructure.
• Effective marketing campaigns emphasizing rapid relief and targeted formulations.

Profitability and Margins

Despite stiff competition, MIDOL’s established brand recognition and loyal customer base bolster gross margins, which potentially range from 50-60%. Operating margins could improve through supply chain optimizations, cost-effective manufacturing, and expanded distribution.

Investment in Innovation

The financial trajectory hinges significantly on innovation. Developing new formulations, such as natural variants or multi-symptom relief options, can unlock additional revenue streams. R&D investments will influence short-term costs but are likely to yield long-term market share gains.

Risks and Challenges

• Market Saturation: Mature markets may experience slowdown without innovation or geographic expansion.
• Regulatory Hurdles: Changes in OTC drug approval processes or labeling requirements could impact product timelines.
• Pricing Pressures: Price competition may compromise profit margins, especially amid increased retailer negotiations.
• Consumer Preference Shifts: Moving toward holistic or natural solutions could diminish demand for traditional analgesic formulations.

Opportunities for Financial Growth

• Geographic Expansion: Emerging markets like India and Southeast Asia present untapped demand for menstrual pain relief.
• Product Line Diversification: Introducing new formats such as gummies or topical applications may attract wider demographics.
• E-commerce Growth: Direct-to-consumer sales via online platforms offer margin improvements and customer engagement.

Conclusion

The market dynamics surrounding MIDOL LIQUID GELS are characterized by steady growth driven by consumer preferences for rapid, targeted menstrual pain relief solutions. While competition and regulatory challenges persist, strategic innovation, expanded market reach, and leveraging digital channels position MIDOL favorably for sustained financial growth. Companies investing in product differentiation and geographic expansion are likely to outperform in this evolving landscape.

---

Key Takeaways

• Steady Growth Potential: MIDOL LIQUID GELS are positioned to grow at a CAGR of 6-8% over the next five years, supported by increasing demand for fast-acting menstrual relief products.
• Market Drivers: Consumer preference for rapid relief, innovation in formulations, and expanded distribution channels sustain growth momentum.
• Competitive & Regulatory Challenges: Market saturation, regulatory hurdles, and shifting consumer preferences necessitate continuous innovation and strategic adaptation.
• Expansion Opportunities: Emerging markets and product diversification into natural or multi-symptom formulations offer lucrative avenues for revenue expansion.
• Digital & Consumer Engagement: E-commerce and targeted marketing will continue to be vital for capturing new segments and enhancing profitability.

---

FAQs

1. What factors most significantly influence MIDOL LIQUID GELS' market growth?
Consumer demand for fast relief, product innovation, expanding distribution channels, and increasing global awareness of women’s health are primary growth drivers.

2. How does regulatory compliance affect MIDOL’s financial outlook?
Regulatory hurdles can increase costs and delay product launches, but compliance ensures market access and mitigates legal risks, thereby stabilizing long-term financial performance.

3. What are the main competitive threats facing MIDOL?
High competition from other OTC analgesics, the rise of natural and holistic menstrual products, and shifting consumer preferences toward organic remedies pose significant threats.

4. How can MIDOL leverage digital channels to enhance financial performance?
By expanding online sales, utilizing targeted digital marketing, and engaging directly with consumers, MIDOL can increase market share and improve profit margins.

5. What future product innovations could impact MIDOL’s market position?
Natural formulations, multi-symptom relief products, alternative delivery formats like gummies, and personalized health solutions could significantly influence MIDOL’s competitive edge.

---

References:

[1] Grand View Research, “Menstrual Health Market Size & Trends,” 2021.